London
· Delayed Price · Currency is GBP · Price in USD Agios Pharmaceuticals Statistics
Total Valuation
Agios Pharmaceuticals has a market cap or net worth of GBP 1.58 billion. The enterprise value is 278.20 million.
| Market Cap | 1.58B |
| Enterprise Value | 278.20M |
Important Dates
The next estimated earnings date is Thursday, February 13, 2025.
| Earnings Date | Feb 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.17% |
| Shares Change (QoQ) | +2.87% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 50.52M |
Valuation Ratios
The trailing PE ratio is 3.13.
| PE Ratio | 3.13 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.55 |
| EV / Sales | 10.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.13 |
Financial Position
The company has a current ratio of 8.99, with a Debt / Equity ratio of 0.04.
| Current Ratio | 8.99 |
| Quick Ratio | 8.44 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.18 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 53.65% and return on invested capital (ROIC) is -19.20%.
| Return on Equity (ROE) | 53.65% |
| Return on Assets (ROA) | -18.17% |
| Return on Capital (ROIC) | -19.20% |
| Revenue Per Employee | 63,701 |
| Profits Per Employee | 1.31M |
| Employee Count | 386 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 13.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +61.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +61.09% |
| 50-Day Moving Average | 45.21 |
| 200-Day Moving Average | 42.58 |
| Relative Strength Index (RSI) | 40.10 |
| Average Volume (20 Days) | 306 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.24 |
Income Statement
In the last 12 months, Agios Pharmaceuticals had revenue of GBP 24.53 million and earned 503.10 million in profits. Earnings per share was 8.80.
| Revenue | 24.53M |
| Gross Profit | -198.90M |
| Operating Income | -303.65M |
| Pretax Income | 542.73M |
| Net Income | 503.10M |
| EBITDA | -299.40M |
| EBIT | -303.65M |
| Earnings Per Share (EPS) | 8.80 |
Balance Sheet
The company has 749.65 million in cash and 45.39 million in debt, giving a net cash position of 1.19 billion.
| Cash & Cash Equivalents | 749.65M |
| Total Debt | 45.39M |
| Net Cash | 1.19B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.21B |
| Book Value Per Share | 21.28 |
| Working Capital | 712.33M |
Cash Flow
In the last 12 months, operating cash flow was -245.59 million and capital expenditures -710,287, giving a free cash flow of -246.30 million.
| Operating Cash Flow | -245.59M |
| Capital Expenditures | -710,287 |
| Free Cash Flow | -246.30M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,238.10% |
| Pretax Margin | 2,212.98% |
| Profit Margin | 2,051.38% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Agios Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.17% |
| Shareholder Yield | -3.17% |
| Earnings Yield | 31.90% |
| FCF Yield | -15.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Agios Pharmaceuticals has an Altman Z-Score of 6.59.
| Altman Z-Score | 6.59 |
| Piotroski F-Score | n/a |